Long-term clinical outcomes after switching from Remicade to Remsima in IBD

July 19, 2017 1:41 PM

A study published on Digestive Diseases and Sciences showed long term data about switching from Remicade to biosimilar version in inflammatory bowel disease (IBD) patients.

Limited data are available on long-term clinical outcomes regarding the switch from Remicade® to the infliximab biosimilar CT-P13 (Remsima/Inflectra) in inflammatory bowel disease (IBD) patients. Therefore the aim of the investigators was to investigate long-term efficacy, safety, pharmacokinetic profile, and immunogenicity.

The study was performed as a single-center prospective observational cohort study following an elective switch from Remicade to Remsima in IBD patients. Following a switch from Remicade to CT-P13, 82% of IBD patients continued treatment through 1 year. And according to the results, disease activity scores and inflammatory markers remained unchanged during follow-up, and no CT-P13-related serious adverse events occurred.

These 1-year data suggest that switching to CT-P13 in Remicade-treated IBD patients is safe and feasible.

Source: ClinicalTrials.gov

Comments are closed

Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.

We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?


Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!